Ontario Industry Updates

Funding Announcement: Ontario Genomics' Genomic Applications Partnership Program (GAPP)

Ontario Genomics iannounced that Round 10 of their Genome Canada’s Genomic Applications Partnership Program is now open.

The Genomic Applications Partnership Program (GAPP) funds public-private research collaborations focused on developing genomics-derived technologies that address opportunities and challenges identified by industry, government, not-for-profits or other “Receptors” of genomics knowledge and tools.

EOI forms are due to Ontario Genomics on November 13th, 2017 at 9 am ET.

Information and Application

Canadian Space Agency Information Session, Oct 26 2017 In Toronto

The Canadian Space Agency (CSA), in partnership with the National Research Council of Canada's Industrial Research Assistance Program (IRAP), wishes to engage the biomedical, health and performance communities as well as space stakeholders to help identify potential Canadian health and biomedical roles in human deep space missions, and explore new ways to collaborate to improve the innovation process in both space and terrestrial health.

Interface Biologics Enters the Neurology Market with 510(k) Clearance of Arkis BioSciences® CerebroFlo™ EVD Catheter with Endexo® Technology

TORONTO, ONTARIO Sept. 26, 2017 - Interface Biologics, a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI's Endexo® technology.

Lumira Capital Leads $7M Series A Financing of Edesa Biotech

MARKHAM, ON, Sept. 20, 2017 Edesa Biotech Inc., a clinical-stage private company announced today the completion of a $7 million Series A financing.  The internationally syndicated investment was led by Lumira Capital and included participation from Pharmascience Inc., Inveready Technology Investment Group and a number of Canadian family offices.

Mars Innovation and Evotec Ag Establish Academic Bridge “Lab150” in Toronto

MaRS Innovation and Evotec AG today announced the launch of “LAB150”.  This transformational Toronto-based partnership will give Canada access to the world-class infrastructure and drug discovery expertise of Evotec, and pair it with cutting-edge drug discovery projects emerging from the 15 Member institutions of MaRS Innovation.

Lab150 is a joint effort by MaRS Innovation and Evotec AG selection and acceleration of early-stage drug discovery projects originating from leading academic institutions and teaching hospitals in Toronto (Canada)